MethylGene Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2012 | $26 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Mar 2011 | $36 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
MethylGene Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Nov 2012).
SEC Form D (revenue range) · Nov 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2012
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of MethylGene Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Arkadii B. Vaisburg | Executive officer | Nov 2012 |
| Charles W. Baum | Executive officer | Nov 2012 |
| Gregory B. Reid | Executive officer | Nov 2012 |
| Jeffrey M. Besterman | Executive officer | Nov 2012 |
| Joseph B. Walewicz | Executive officer | Nov 2012 |
| Klaus B. Kepper | Executive officer | Nov 2012 |
| Martin Godbout | Executive officer | Nov 2012 |
| Rachel B. Humphrey | Executive officer | Nov 2012 |
| Arkadil B. Vaisburg | Executive officer | Sep 2012 |
| Charles R. Grubsztajn | Executive officer | Sep 2012 |
| Charles W. Baum | Director | Nov 2012 |
| Henry J. Fuchs | Director | Nov 2012 |
| Martin Godbout | Director | Nov 2012 |
| Peggy W. Mulligan | Director | Nov 2012 |
| Peter W. Thompson | Director | Nov 2012 |
| Rodney W. Lappe | Director | Nov 2012 |
| Charles R. Grubsztajn | Director | Sep 2012 |
| Colin R. Mallet | Director | Sep 2012 |
| Louis W. Lacasse | Director | Sep 2012 |
| Peggy R. Mulligan | Director | Sep 2012 |
| Peter B. Thompson | Director | Sep 2012 |
| Andre Archimbaud | Director | Apr 2011 |
| David J. Drutz | Director | Apr 2011 |
| Jay R. Moorin | Director | Apr 2011 |
| Louis J. Lacasse | Director | Apr 2011 |